Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis

Brain

Volumn 132, Issue 6, 2009, Pages 1536-1544

  Dalakas, Marinos C ^a,d   Rakocevic, Goran ^a   Schmidt, Jens ^a   Salajegheh, Mohammad ^a   McElroy, Beverly ^a   Harris Love, Michael O ^b   Shrader, Joseph A ^b   Levy, Ellen W ^b   Dambrosia, James ^a   Kampen, Robert L ^c   Bruno, David A ^c   Kirk, Allan D ^c  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Alemtuxumab; Endomysial inflammation; IBM; Lymphocyte depletion; Muscle degeneration; Muscle inflammation; Stressor molecules

Indexed keywords

ALEMTUZUMAB; ALPHA CRYSTALLIN; FAS ANTIGEN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; AUTACOID; CANCER ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; HUMAN; HYPOTENSION; INCLUSION BODY MYOSITIS; MAJOR CLINICAL STUDY; MALE; MUSCLE BIOPSY; MUSCLE STRENGTH; PERIPHERAL LYMPHOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; T LYMPHOCYTE; AGED; BIOPSY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONVALESCENCE; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; SKELETAL MUSCLE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; BIOPSY; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; MUSCLE STRENGTH; MUSCLE, SKELETAL; MYOSITIS, INCLUSION BODY; RECOVERY OF FUNCTION; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 67649399221     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awp104     Document Type: Article

References (27)

1. Armstrong N, Buckley P, Oberley T, Fechner J Jr, Dong Y, Hong X, et al. Analysis of primate renal allografts following T cell depletion with anti-CD3-CRM9. Transplantation 1998; 66: 5-13.
2. Askanas V, Engel WK. Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology 2006; 66 (2 Suppl 1): S39-48.
3. Badrising UA, Schreuder GM, Giphart MJ, Geleijns K, Verschuuren JJ, Wintzen AR, et al. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology 2004; 63: 2396-8.
4. Banwell BL, Engel AG. AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology 2000; 54: 1033-41.
5. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008; 70: 418-24.
6. Coles AJ, Lox A, Le Page, Jones J, Trip SA, Deans J, et al. The window of therapeutic opportunity in multiple sclerosis: evidence for monoclonal antibody therapy. J Neurol 2006; 253: 98-108.
7. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991; 325: 1487-98.
8. Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol 2004; 17: 561-7.
9. Dalakas MC. Sporadic inclusion body myositis-diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2006; 2: 437-47.
10. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion body myositis with IVIg: a double-blind, placebo-control study. Neurology 1997; 48: 712-6.
11. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001; 56: 323-7.
12. Flynn JM, Byrd JC. Campath-1H monoclonal antibody therapy. Curr Opin Oncol 2000; 12: 574-81.
13. Hale G, Waldmann H. From laboratory to clinic: the story of CAMPATH-1. Methods Mol Med 2000; 40: 243-66.
14. Hale G, Dyer MJS, Clark MR, Phillips JM, Marcus R, Riechmann L, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; 2: 1394-9.
15. Kirk AD, Hale DA, Mannon RB, Kleiner DE, Hoffmann SC, Kampen RL, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody Campath-1H. Transplantation 2003; 76: 120-9.
16. Koffman BM, Rugiero M, Dalakas MC. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 1998; 21: 115-7.
17. Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 2003; 61: 260-2.
18. Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007; 620-31.
19. Mikol J, Engel AG. Inclusion body myositis. In: Engel AG, Franzini-Armstrong C, editors. Myology. 3rd edn., New York, NY: McGraw-Hill Book Co.; 2004. p. 1367-88.
20. Muntzing K, Lindberg C, Moslemi AR, Oldfors A. Inclusion body myositis: clonal expansions of muscle-infiltrating T cells persist over time. Scand J Immunol 2003; 58: 195-200.
21. Nagaraju K, Casciola-Rosen L, Lundberg I, Rawat R, Cutting S, Thapliyal R, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005; 52: 1824-35.
22. Pearl JP, Paris J, Hale DA, Hoffmann SC, Bernstein WB, McCoy, et al. Immunocometent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5: 465-74.
23. Reiff A. A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation. Hematology 2005; 10: 79-93.
24. Salajegheh M, Rakocevic G, Raju R, Shatunov A, Goldfarb LG, Dalakas MC. T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis. Neurology 2007; 69: 1672-9.
25. Schmidt J, Barthel K, Wrede A, Salajegheh M, Bähr M, Dalakas MC. Interrelation of inflammation and APP in sIBM: IL-1b induces accumulation of b-amyloid in skeletal muscle. Brain 2008; 131: 1228-40.
26. The CAMMS233Trial investigation. N Engl J Med 2008; 359: 1786-801.
27. Weinblatt ME, Maddison PJ, Bulpitt KJ, Hazleman BL, Urowitz MB, Sturrock RD, et al. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum 1995; 38: 1589-94.